Maxim Group reiterated coverage on Cyclo Therapeutics with a new price target

2/10/21 8:07:06 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Maxim Group reiterated coverage of Cyclo Therapeutics with a rating of Buy and set a new price target of $25.00 from $12.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CYTH

Date	Price Target	Rating	Analyst